Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case–Control Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case–Control Study

Published:2020-07-02 Issue:3 Volume:7 Page:191-203
ISSN:2199-1154
Container-title:Drugs - Real World Outcomes
language:en
Short-container-title:Drugs - Real World Outcomes

Author:

Farhat Nawal^ORCID,Birkett Nicholas^ORCID,Haddad Nisrine^ORCID,Fortin Yannick^ORCID,Momoli Franco,Wen Shi Wu^ORCID,Wielgosz Andreas^ORCID,McNair Doug S.^ORCID,Mattison Donald R.^ORCID,Krewski Daniel^ORCID

Funder

Canadian Institutes of Health Research - Doctoral Award

McLaughlin Center for Population Health Risk Assessment

University of Ottawa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40801-020-00204-9.pdf

Reference39 articles.

1. Pelliccia F, Rollini F, Marazzi G, Greco C, Gaudio C, Angiolillo DJ. Drug–drug interactions between clopidogrel and novel cardiovascular drugs. Eur J Pharmacol. 2015;765:332–6. https://doi.org/10.1016/j.ejphar.2015.08.059 .

2. Bhatt B, Scheiman J, Abraham N, Antman E, Chan F, Furberg F, et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2008;52:1502–17. https://doi.org/10.1016/j.jacc.2008.08.002 .

3. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92–9. https://doi.org/10.1124/dmd.109.029132 .

4. Farhat N, Fortin Y, Haddad N, Birkett N, Mattison D, Momoli F, et al. Systematic review and meta-analysis of adverse cardiovascular events associated with concomitant use of proton pump inhibitors and antiplatelet agents. Crit Rev Toxicol. 2019. https://doi.org/10.1080/10408444.2019.1583167 .

5. Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol. 2017;69:1154–64. https://doi.org/10.1002/art.40084 .

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors associated with an increased risk of mortality in elderly: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2023-12-26

2. Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations;Cardiology and Therapy;2023-11-10

3. Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25

4. The State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies;American Journal of Epidemiology;2023-10-17

5. Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view;World Journal of Cardiology;2023-08-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3